Phase II Hedgehog Inhibitor for Myelodysplastic Syndrome (MDS)
Status:
Completed
Trial end date:
2021-06-10
Target enrollment:
Participant gender:
Summary
This study is being done to see how safe an investigational drug is and test how well it will
work to help people with refractory/relapsed myelodysplastic syndrome (MDS) or chronic
myelomonocytic leukemia (CMML).
Phase:
Phase 2
Details
Lead Sponsor:
H. Lee Moffitt Cancer Center and Research Institute